AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9849291 — intervention group
Group type: COMPARATOR
Intervention: Cuffed tracheal tube
Number of subjects: 60
Study 9551877 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day oral salt load (150 mmol NaCl extra per day)
Number of subjects: 6
Study 9551877 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 6
Study 1833903 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone therapy
Number of subjects: 31
Study 1833903 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 31
Study 6315447 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural and synthetic oestrogen administration
Number of subjects: 0
Study 31318184 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 811
Study 31318184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 811
Study 29204851 — intervention group
Group type: EXPERIMENTAL
Intervention: Training students once on three different scenarios of PAEs
Number of subjects: 85
Study 29204851 — intervention group
Group type: COMPARATOR
Intervention: Training students three times on the same scenario of PAE
Number of subjects: 85
Study 29204851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (varying practice and repetitive practice)
Number of subjects: 85
Study 26873681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 0
Study 26873681 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 25046547 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg/qd) and calcitriol (2.5 μg/qd)
Number of subjects: 386
Study 25046547 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (20 mg/qd)
Number of subjects: 386
Study 22269042 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-containing functional food (300 mg DHA, 92 kcal) consumed an average of 5 days/week from 24 weeks gestation until delivery
Number of subjects: 48
Study 22269042 — intervention group
Group type: COMPARATOR
Intervention: Placebo bars
Number of subjects: 48
Study 20201608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (EE) 30 microg/DRSP 3 mg (n = 573)
Number of subjects: 768
Study 20201608 — intervention group
Group type: COMPARATOR
Intervention: Ethinylestradiol (EE) 30 microg/DSG 150 microg (n = 195)
Number of subjects: 768
Study 20201608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (EE) 30 microg/DRSP 3 mg
Number of subjects: 768
Study 18684735 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa 60 microg
Number of subjects: 0
Study 18684735 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa 120 microg
Number of subjects: 0
Study 18684735 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa 180 microg
Number of subjects: 0
Study 18684735 — intervention group
Group type: COMPARATOR
Intervention: Recombinant follicle‐stimulating hormone (rFSH) 150 IU
Number of subjects: 0
Study 15844695 — intervention group
Group type: EXPERIMENTAL
Intervention: HCl infusion
Number of subjects: 3
Study 15844695 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 3
Study 12174523 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9640431 — intervention group
Group type: EXPERIMENTAL
Intervention: Training strategies to improve learning of new names
Number of subjects: 0
Study 9640431 — intervention group
Group type: EXPERIMENTAL
Intervention: Training strategies to improve retrieval of familiar names
Number of subjects: 0
Study 9640431 — intervention group
Group type: COMPARATOR
Intervention: Control memory tests with normal subjects receiving no training
Number of subjects: 0
Study 7845419 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of miconazole 55 mg/g denture lacquer (single application)
Number of subjects: 50
Study 7845419 — intervention group
Group type: COMPARATOR
Intervention: Commercially available miconazole 2% gel (applied four times daily for 2 weeks)
Number of subjects: 50
Study 2840035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur 600 mg p.o. for 8 weeks followed by 4 weeks rest (4 courses)
Number of subjects: 587
Study 2840035 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy (control group)
Number of subjects: 587
Study 29672144 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training for community health workers (CHWs); Training sessions to enhance communication skills.
Number of subjects: 900
Study 29672144 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (PWID receiving services from trained CHWs);
Number of subjects: 900
Study 29672144 — intervention group
Group type: COMPARATOR
Intervention: Control group (PWID receiving services from untrained CHWs);
Number of subjects: 900
Study 27647222 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense TCF regimen with 30% dose reduction
Number of subjects: 119
Study 27647222 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense TCF regimen without dose reduction
Number of subjects: 119
Study 24820281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin combined with intrathecal sufentanil infusion
Number of subjects: 60
Study 24820281 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with intrathecal sufentanil infusion
Number of subjects: 60
Study 24820281 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine sulfate controlled‐release tablet
Number of subjects: 60
Study 22239292 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management initiative (Coordinator of Services for Elderly)
Number of subjects: 351
Study 22239292 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 351
Study 20804445 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg + metformin XR
Number of subjects: 93
Study 20804445 — intervention group
Group type: COMPARATOR
Intervention: Placebo + metformin XR
Number of subjects: 93
Study 18404537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbate pre-treatment
Number of subjects: 12
Study 18404537 — intervention group
Group type: COMPARATOR
Intervention: Maximal exercise
Number of subjects: 12
Study 16866686 — intervention group
Group type: EXPERIMENTAL
Intervention: Current drivers
Number of subjects: 183
Study 16866686 — intervention group
Group type: COMPARATOR
Intervention: Former drivers
Number of subjects: 183
Study 16866686 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 183
Study 12499076 — intervention group
Group type: EXPERIMENTAL
Intervention: Liv.52 (n = 40)
Number of subjects: 80
Study 12499076 — intervention group
Group type: COMPARATOR
Intervention: Placebo (controls)
Number of subjects: 80
Study 10641162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin beta-cyclodextrin inclusion complex dental implants
Number of subjects: 10
Study 10641162 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study 8890721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal GH 0.05 IU/kg
Number of subjects: 16
Study 8890721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal GH 0.10 IU/kg
Number of subjects: 16
Study 8890721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal GH 0.20 IU/kg
Number of subjects: 16
Study 8890721 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous GH 0.10 IU/kg
Number of subjects: 16
Study 8890721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GH 0.015 IU/kg
Number of subjects: 16
Study 1426662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan (a (1‐‐‐‐3)‐beta‐D‐glucan with (1‐‐‐‐6)‐beta‐D‐glucopyranoside branches)
Number of subjects: 0
Study 1426662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan
Number of subjects: 0
Study 1426662 — intervention group
Group type: EXPERIMENTAL
Intervention: Host Defence Potentiators (HDPs) such as lentinan
Number of subjects: 0
Study 1426662 — intervention group
Group type: EXPERIMENTAL
Intervention: HDPs such as lentinan
Number of subjects: 0
Study 3937598 — intervention group
Group type: EXPERIMENTAL
Intervention: CP (cyclophosphamide 1 g/m2 plus cisplatin 60 mg/m2)
Number of subjects: 181
Study 3937598 — intervention group
Group type: COMPARATOR
Intervention: HCAP (hexamethylmelamine 150 mg/m2/day X 7, cyclophosphamide 400 mg/m2, doxorubicin 30 mg/m2, and cisplatin 60 mg/m2)
Number of subjects: 181
Study 3937598 — intervention group
Group type: EXPERIMENTAL
Intervention: HCAP
Number of subjects: 181
Study 3937598 — intervention group
Group type: EXPERIMENTAL
Intervention: CP
Number of subjects: 181
Study 29066293 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (aerobic exercise or stretching/toning, 3×60min/week) plus mental activity (computer‐based cognitive training or educational DVDs, 3×60min/week)
Number of subjects: 126
Study 29066293 — intervention group
Group type: COMPARATOR
Intervention: Control group (light exercise)
Number of subjects: 126
Study 27863613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with lavender essential oil
Number of subjects: 90
Study 27863613 — intervention group
Group type: COMPARATOR
Intervention: Placebo (massage with almond oil)
Number of subjects: 90
Study 27863613 — intervention group
Group type: COMPARATOR
Intervention: Control (without massage)
Number of subjects: 90
Study 24680229 — intervention group
Group type: EXPERIMENTAL
Intervention: I DECIDE program (3 days training)
Number of subjects: 249
Study 24680229 — intervention group
Group type: EXPERIMENTAL
Intervention: I DECIDE program (half/1 day training)
Number of subjects: 249
Study 24680229 — intervention group
Group type: EXPERIMENTAL
Intervention: I DECIDE program
Number of subjects: 249
Study 22613197 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet CPAP
Number of subjects: 50
Study 22613197 — intervention group
Group type: COMPARATOR
Intervention: Control (air-entrainment mask, F(IO(2)) 0.4)
Number of subjects: 50
Study 20507398 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week (eow)
Number of subjects: 169
Study 20507398 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg loading dose at week 0 followed by adalimumab 40 mg eow starting at week 2
Number of subjects: 169
Study 20507398 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg eow
Number of subjects: 169
Study 20507398 — intervention group
Group type: COMPARATOR
Intervention: Placebo eow
Number of subjects: 169
Study 17490955 — intervention group
Group type: EXPERIMENTAL
Intervention: Established group (18-session intervention with hypertension recommendations)
Number of subjects: 658
Study 17490955 — intervention group
Group type: EXPERIMENTAL
Intervention: Established+DASH group (18-session intervention with DASH diet)
Number of subjects: 658
Study 17490955 — intervention group
Group type: COMPARATOR
Intervention: Advice group (1 session on topics)
Number of subjects: 658
Study 17490955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis by ED change tertiles
Number of subjects: 658
Study 15319313 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorization of pitch direction (rising versus falling)
Number of subjects: 0
Study 15319313 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorization of duration (short versus long)
Number of subjects: 0
Study 12360166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker implantation (VVIR or DDDR mode)
Number of subjects: 398
Study 10204812 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term epidural anaesthesia
Number of subjects: 0
Study 10204812 — intervention group
Group type: COMPARATOR
Intervention: Bed rest, diet control, and antihypertensive drug (control group)
Number of subjects: 0
Study 7491697 — intervention group
Group type: EXPERIMENTAL
Intervention: BT563 (anti-CD25 mAb), cyclosporine, and steroids
Number of subjects: 69
Study 7491697 — intervention group
Group type: COMPARATOR
Intervention: Placebo and cyclosporine-steroids
Number of subjects: 69
Study 2407096 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD, 500 kcal/d)
Number of subjects: 13
Study 2407096 — intervention group
Group type: COMPARATOR
Intervention: Balanced-deficit diet (BDD, 1200 kcal/d)
Number of subjects: 13
Study 7364141 — intervention group
Group type: EXPERIMENTAL
Intervention: Betnovate cream (betamethasone 17‐valerate 0.1%)
Number of subjects: 0
Study 30476225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast fourth ventricle (CFV) present
Number of subjects: 238
Study 30476225 — intervention group
Group type: COMPARATOR
Intervention: No cast fourth ventricle (CFV)
Number of subjects: 238
Study 30476225 — intervention group
Group type: EXPERIMENTAL
Intervention: CFV
Number of subjects: 238
Study 28338208 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT technology combined with visual root canal recurrence (observation group)
Number of subjects: 56
Study 28338208 — intervention group
Group type: COMPARATOR
Intervention: CBCT technology combined with conventional root canal therapy (control group)
Number of subjects: 56
Study 25719984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 50
Study 25093483 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 61
Study 25093483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 21299274 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive behavioral therapy (T-CBT) for 16 sessions over 20 weeks
Number of subjects: 85
Study 21299274 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual through the CBOC
Number of subjects: 85
Study 19118701 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-125 brachytherapy
Number of subjects: 650
Study 16732839 — intervention group
Group type: COMPARATOR
Intervention: SQ sumatriptan 6 mg
Number of subjects: 40
Study 16732839 — intervention group
Group type: EXPERIMENTAL
Intervention: TMB 200 mg and DPH 25 mg (TMB/DPH)
Number of subjects: 40
Study 15616486 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic eye drops, a pacifier, plus three doses of 24% sucrose
Number of subjects: 30
Study 15616486 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic eye drops, a pacifier, plus three doses of sterile water
Number of subjects: 30
Study 11459911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP)
Number of subjects: 29
Study 11459911 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 29
Study 8985627 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5% timolol gel
Number of subjects: 40
Study 8985627 — intervention group
Group type: COMPARATOR
Intervention: Oral sustained-release acetazolamide
Number of subjects: 40
Study 8424561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 1 mg
Number of subjects: 544
Study 8424561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 544
Study 8424561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 544
Study 8424561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study 2888417 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg morphine (MST 30)
Number of subjects: 60
Study 2888417 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lormetazepam (Noctamid)
Number of subjects: 60
Study 2888417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31986451 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA)
Number of subjects: 170
Study 30526616 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinct reminders
Number of subjects: 375
Study 30526616 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders including a rationale
Number of subjects: 375
Study 30526616 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 375
Study 30526616 — intervention group
Group type: COMPARATOR
Intervention: No SMS reminders
Number of subjects: 375
Study 30526616 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall accelerometer wear data
Number of subjects: 375
Study 30526616 — intervention group
Group type: EXPERIMENTAL
Intervention: Equivalence testing
Number of subjects: 375
Study 27248716 — intervention group
Group type: EXPERIMENTAL
Intervention: WTC10 intervention group
Number of subjects: 28
Study 27248716 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 23826643 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP‐2/ACS
Number of subjects: 39
Study 23826643 — intervention group
Group type: COMPARATOR
Intervention: CS
Number of subjects: 39
Study 22527424 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% topical imiquimod cream
Number of subjects: 463
Study 22527424 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-imiquimod therapy (antibiotic creams, topical steroids, emollients)
Number of subjects: 463
Study 21347737 — intervention group
Group type: EXPERIMENTAL
Intervention: ISH group (systolic blood pressure > 140 mmHg)
Number of subjects: 312
Study 21347737 — intervention group
Group type: COMPARATOR
Intervention: Normotensive group (systolic blood pressure < 140 mmHg)
Number of subjects: 312
Study 18347392 — intervention group
Group type: EXPERIMENTAL
Intervention: Racol (omega-3 fatty acid-containing diet) at a maximum dose of 600 mL/day during CRT
Number of subjects: 20
Study 18347392 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Rakol)
Number of subjects: 20
Study 16750288 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy (SET)
Number of subjects: 29
Study 12749508 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 1 mg/d
Number of subjects: 124
Study 12749508 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 1 mg/d
Number of subjects: 124
Study 11085960 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive free-breathing MR technique for coronary vessel wall imaging
Number of subjects: 10
Study 8618295 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy
Number of subjects: 0
Study 8618295 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 0
Study 1534774 — intervention group
Group type: EXPERIMENTAL
Intervention: buserelin acetate
Number of subjects: 246
Study 1534774 — intervention group
Group type: EXPERIMENTAL
Intervention: triptorelin
Number of subjects: 246
Study 1534774 — intervention group
Group type: EXPERIMENTAL
Intervention: leuprorelin
Number of subjects: 246
Study 3844162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (N = 44)
Number of subjects: 86
Study 3844162 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 42)
Number of subjects: 86
Study 31298627 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous neuromuscular electrical stimulation (t‐NMES)
Number of subjects: 10
Study 31298627 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 10
Study 31298627 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (control)
Number of subjects: 10
Study 29282469 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine 28 mg
Number of subjects: 67
Study 29282469 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine 56 mg
Number of subjects: 67
Study 29282469 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine 84 mg
Number of subjects: 67
Study 29282469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 29282469 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine (all doses combined)
Number of subjects: 67
Study 29282469 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine (during open-label phase)
Number of subjects: 67
Study 29282469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during open-label phase)
Number of subjects: 67
Study 27180030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (child care providers received two 3-hour workshops and a training manual)
Number of subjects: 83
Study 27180030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 83
Study 27180030 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard curriculum)
Number of subjects: 83
Study 25158897 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 5 ml (25 mg/ml) tranexamic acid (TXA) and 5 ml analgesic containing epinephrine (3 μg/ml) injected at several points into the posterior capsule before installation of the prosthesis; 10 ml TXA and 10 ml analgesic containing epinephrine injected into the periosteum, synovium, joint capsule, tendons, and deep fascia before tourniquet release; TXA solution (20 ml) injected into the articular cavity after wound closure; drainage tube clamped for 4 h.
Number of subjects: 90
Study 25158897 — intervention group
Group type: COMPARATOR
Intervention: Group B: Injection of analgesic containing epinephrine into soft tissue, control of active bleeding, and clamping of the drainage tube for 4 h only.
Number of subjects: 90
Study 24654216 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (25 mg daily)
Number of subjects: 69
Study 24654216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 24654216 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 69
Study 24654216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study 20619623 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 41
Study 20619623 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 41
Study 20619623 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 600 μg
Number of subjects: 41
Study 20619623 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 μg
Number of subjects: 41
Study 20619623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 17178506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonvital endodontium
Number of subjects: 0
Study 17178506 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute peroperative inflammation
Number of subjects: 0
Study 17178506 — intervention group
Group type: EXPERIMENTAL
Intervention: Low extraction forces
Number of subjects: 0
Study 17178506 — intervention group
Group type: COMPARATOR
Intervention: Endodontic status
Number of subjects: 0
Study 17178506 — intervention group
Group type: COMPARATOR
Intervention: Tooth type, root-form, and age of patients
Number of subjects: 0